论文部分内容阅读
目的:对甘露醇联合人血白蛋白+呋塞米治疗手足口病重型疗效进行观察和分析。方法:选择2014年01月到2014年11月在本院进行治疗的手足口病重型患儿52例,28例为女性患儿,24例为男性患儿,年龄6个月~5岁,平均年龄(2.0±0.3)岁。在入院后即给予甘露醇联合人血白蛋白+呋塞米进行治疗,对治疗前后患者的神经系统症状改善进行比较。结果:患儿经治疗后均康复出院;治疗前患儿的神经症状评分为(7.74±0.79)分,治疗后3d评分为(6.30±0.63)分,治疗后7d,评分为(5.29±0.50)分,与治疗前相比差异均具有显著性(P<0.05)。结论:甘露醇联合人血白蛋白+呋塞米应用于手足口病重型的治疗中,具有良好的疗效,能够有效缓解患儿的神经系统症状,抑制病情进展,建议在临床上推广应用。
Objective: To observe and analyze the efficacy of mannitol combined with human serum albumin and furosemide in the treatment of HFMD. METHODS: Fifty-two HFMD children treated in our hospital from January 2014 to November 2014 were selected, 28 were female and 24 were male with a mean age of 6 months to 5 years Age (2.0 ± 0.3) years old. Mannitol combined with human serum albumin + furosemide was administered after admission to compare the improvement of neurological symptoms in patients before and after treatment. Results: The children were all recovered after treatment. The score of neurological symptoms before treatment was (7.74 ± 0.79), the score was (6.30 ± 0.63) 3d after treatment and (5.29 ± 0.50) on the 7th day after treatment. Points, compared with before treatment, the differences were significant (P <0.05). Conclusion: Mannitol combined with human serum albumin + furosemide has a good curative effect in the treatment of severe hand-foot-mouth disease. It can effectively relieve the neurological symptoms of children and restrain the progression of the disease. It is recommended to be applied clinically.